ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,114Medicare Part D Prescriptions Filled, Including Refills

Rank: 48 out of 546

$742K Total Retail Price of All Prescriptions

Rank: 19 out of 546

272 Patients Receiving at Least One Drug in Part D
46%Patients 65 Years and Older
87% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

16% of this provider’s 272 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

24% of this provider’s 272 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 3,270 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$91 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
HYDROCODONE-ACETAMINOPHEN 268 73 S3 1 8
SIMVASTATIN 266 129 2 2
LISINOPRIL 254 127 3 1
OMEPRAZOLE 253 112 4 4
METOPROLOL SUCCINATE 159 99 5 17
LISINOPRIL-HYDROCHLOROTHIAZIDE 144 73 6 49
ADVAIR DISKUS 144 71 6 20
SERTRALINE HCL 136 41 8 14
METFORMIN HCL 136 75 8 10
CITALOPRAM HBR 128 56 10 21
WARFARIN SODIUM 126 39 11 13
OXYCODONE HCL 125 24 S2 12 15
HYDROCHLOROTHIAZIDE 115 65 13 7
IBUPROFEN 111 24 14 70
CYMBALTA 108 30 15 37
ZOLPIDEM TARTRATE 103 26 16 26
CRESTOR 101 36 17 36
FLUOXETINE HCL 100 21 18 39
SUBOXONE 98 0 19 40
AMLODIPINE BESYLATE 95 84 20 9
GABAPENTIN 94 30 21 16
DOXEPIN HCL 90 33 22 185
CYCLOBENZAPRINE HCL 89 20 R 23 34
LEVOTHYROXINE SODIUM 86 50 24 3
FUROSEMIDE 85 55 25 5
METOPROLOL TARTRATE 84 48 26 6
RANITIDINE HCL 84 18 26 23
PANTOPRAZOLE SODIUM 83 27 28 18
DEXILANT 80 0 29 109
PROAIR HFA 78 30 30 27
HYDROXYZINE PAMOATE 78 22 R 30 153
CARBAMAZEPINE 77 23 32 120
LITHIUM CARBONATE 73 0 33 193
ATENOLOL 73 28 33 12
SPIRIVA 69 42 35 28
BUPROPION XL 69 0 35 93
ROPINIROLE HCL 66 39 37 64
LYRICA 65 0 38 69
VENTOLIN HFA 64 21 39 63
NIASPAN 59 0 40 156
RISPERIDONE 57 0 41 47
FLUTICASONE PROPIONATE 57 0 41 42
COMBIVENT 57 31 41 71
TRAZODONE HCL 56 39 44 25
CARVEDILOL 56 24 44 56
AZITHROMYCIN 55 20 46 55
MELOXICAM 54 34 47 58
TRICOR 54 24 47 128
LAMOTRIGINE 53 0 49 125
TRAMADOL HCL 52 18 50 19
FAMOTIDINE 51 26 51 53
AMPHETAMINE SALT COMBO 51 0 S2 51 178
LIDODERM 50 41 53 73
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.